Integra LifeSciences Holdings Corporation (NASDAQ:IART) was downgraded by equities research analysts at Wells Fargo & Company to a “market perform” rating in a research note issued to investors on Sunday.
Other analysts also recently issued reports about the stock. Zacks Investment Research downgraded shares of Integra LifeSciences Holdings Corporation from a “buy” rating to a “hold” rating in a research note on Wednesday. Barclays PLC reissued an “equal weight” rating and set a $53.00 target price (up from $47.00) on shares of Integra LifeSciences Holdings Corporation in a research note on Tuesday, September 12th. Cantor Fitzgerald reissued an “overweight” rating and set a $65.00 target price on shares of Integra LifeSciences Holdings Corporation in a research note on Monday, July 10th. BidaskClub downgraded shares of Integra LifeSciences Holdings Corporation from a “buy” rating to a “hold” rating in a research note on Monday, July 24th. Finally, Jefferies Group LLC reissued a “buy” rating on shares of Integra LifeSciences Holdings Corporation in a research note on Sunday, September 10th. Seven analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $53.91.
Integra LifeSciences Holdings Corporation (NASDAQ:IART) traded down 2.61% during trading on Friday, reaching $46.32. The company had a trading volume of 2,706,160 shares. The firm has a market capitalization of $3.62 billion, a P/E ratio of 56.49 and a beta of 0.71. Integra LifeSciences Holdings Corporation has a 52-week low of $37.71 and a 52-week high of $56.42. The company has a 50-day moving average of $50.38 and a 200-day moving average of $49.99.
Integra LifeSciences Holdings Corporation (NASDAQ:IART) last posted its quarterly earnings results on Thursday, October 26th. The life sciences company reported $0.45 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.47 by ($0.02). The company had revenue of $278.83 million during the quarter, compared to the consensus estimate of $286.00 million. Integra LifeSciences Holdings Corporation had a net margin of 4.52% and a return on equity of 16.59%. Integra LifeSciences Holdings Corporation’s quarterly revenue was up 11.4% on a year-over-year basis. During the same period in the prior year, the company posted $0.93 EPS. Analysts expect that Integra LifeSciences Holdings Corporation will post $1.89 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Integra LifeSciences Holdings Corporation (IART) Downgraded by Wells Fargo & Company” was first reported by Community Financial News and is the property of of Community Financial News. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece can be read at https://www.com-unik.info/2017/10/29/integra-lifesciences-holdings-corporation-iart-downgraded-by-wells-fargo-company.html.
In related news, Director Donald E. Morel, Jr. purchased 10,000 shares of the stock in a transaction dated Friday, August 4th. The shares were acquired at an average cost of $49.25 per share, for a total transaction of $492,500.00. Following the acquisition, the director now directly owns 29,612 shares in the company, valued at approximately $1,458,391. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Barbara B. Hill purchased 5,050 shares of the stock in a transaction dated Tuesday, August 1st. The shares were bought at an average price of $49.33 per share, for a total transaction of $249,116.50. Following the completion of the acquisition, the director now owns 44,772 shares in the company, valued at $2,208,602.76. The disclosure for this purchase can be found here. Over the last 90 days, insiders have bought 17,550 shares of company stock worth $864,842. 21.50% of the stock is currently owned by corporate insiders.
Several institutional investors have recently bought and sold shares of IART. BlackRock Inc. grew its holdings in shares of Integra LifeSciences Holdings Corporation by 307,726.8% during the 1st quarter. BlackRock Inc. now owns 7,455,564 shares of the life sciences company’s stock valued at $314,104,000 after acquiring an additional 7,453,142 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Integra LifeSciences Holdings Corporation by 116.7% in the first quarter. Vanguard Group Inc. now owns 5,656,048 shares of the life sciences company’s stock worth $238,289,000 after purchasing an additional 3,046,488 shares in the last quarter. Capital Research Global Investors boosted its holdings in Integra LifeSciences Holdings Corporation by 227.0% in the second quarter. Capital Research Global Investors now owns 3,897,288 shares of the life sciences company’s stock worth $212,441,000 after purchasing an additional 2,705,488 shares in the last quarter. Janus Henderson Group PLC bought a new stake in Integra LifeSciences Holdings Corporation in the second quarter worth $112,068,000. Finally, Dimensional Fund Advisors LP boosted its holdings in Integra LifeSciences Holdings Corporation by 96.5% in the first quarter. Dimensional Fund Advisors LP now owns 1,679,095 shares of the life sciences company’s stock worth $70,741,000 after purchasing an additional 824,496 shares in the last quarter. Institutional investors and hedge funds own 84.90% of the company’s stock.
About Integra LifeSciences Holdings Corporation
Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.
What are top analysts saying about Integra LifeSciences Holdings Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Integra LifeSciences Holdings Corporation and related companies.